Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B001 in Advanced Colorectal and Gastric Cancer
NCT05039944Phase 2Terminated
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab in colorectal cancer (CRC), gastric cancer (GC), sponsored by Biokin Pharmaceutical. Started Nov 2021; status: terminated.
02
Drugs
izalontamab
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT05039944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039944.